An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.
about
Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-AnalysisReporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals.Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label StudyOpioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group studyRepeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic painEffectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.Hydromorphone-OROS formulation.End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
P2860
Q33700472-16700507-9DA5-4760-AAAE-1E32D2A1C5B1Q33919787-2CBBE17C-CD31-46A2-A96B-6612BD8D2F52Q34386010-658FC3CE-9EFB-4426-83FF-D4F6416CE0A1Q34773536-895A38DE-5FD0-4D15-B660-810B6748906CQ36365111-FF0A4F80-98FB-4982-AF05-5D84F7708819Q36407485-F452ACB4-CC40-4E76-9C49-AD317A828633Q36821199-70AC2200-70B0-4B08-B449-2E86D98BD8A9Q37404917-F1F4F721-2886-445B-8BC0-44B4934F1F1AQ37733564-F4F415BE-7A64-4FD8-A111-7C5D2CDD0421Q38174282-5C1F8DA6-2DE0-4CC6-8E8F-F44C12684DCBQ39217581-B08319E8-7091-49CF-A008-00EF8051B40BQ48248784-F96E985F-787A-4808-8472-9FDFF626DF01
P2860
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@ast
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@en
type
label
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@ast
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@en
prefLabel
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@ast
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@en
P2093
P2860
P356
P1433
P1476
An open-label, 1-year extensio ...... ents with chronic cancer pain.
@en
P2093
Alberto Tuca
John Thipphawong
Magdi Hanna
P2860
P2888
P356
10.1186/1472-684X-8-14
P577
2009-09-15T00:00:00Z
P6179
1053100942